Feb22 event *remove after event end

Gain Therapeutics' 2024 R&D update with KOL and Analyst Insight

Register Here >>

scroll

scroll-down

OUR DRUG DISCOVERY PLATFORM MAGELLAN™

OUR DRUG DISCOVERY PLATFORM MAGELLAN™

 

By leveraging AI-supported 3D structural biology and supercomputer-powered proprietary physics-based models, Gain’s Magellan™ platform is able to identify novel allosteric binding sites on disease-implicated proteins and exploit their untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.

 

Our Platform >>

magellan-logo